Characteristics of the population at diagnosis
| Parameters . | Cohort . | ET . | PV . | Other MPNs . | ||||
|---|---|---|---|---|---|---|---|---|
| Nb/median . | % or range . | Nb/median . | % or range . | Nb/median . | % or range . | Nb/median . | % or range . | |
| Numbers | 444 | 318 | 71.6 | 81 | 18.2 | 45 | 10.2 | |
| Female | 321 | 72.3 | 248 | 78 | 39 | 48.1 | 34 | 75.6 |
| Age | 20.4 | 2-25 | 20.6 | 2-25 | 19.7 | 2.3-25 | 20.1 | 5.3-24.4 |
| Symptoms | ||||||||
| Plethoric face | 15 | 3.9 | 2 | 0.7 | 13 | 21.3 | 0 | 0 |
| Aquagenic pruritus | 22 | 5.6 | 9 | 3.2 | 13 | 19.7 | 0 | 0 |
| Hyperviscosity | 127 | 34.5 | 91 | 34.2 | 27 | 42.2 | 9 | 23.7 |
| Microvascular symptoms | 43 | 10.8 | 33 | 11.6 | 4 | 5.8 | 6 | 14 |
| Constit symptoms | 24 | 6.2 | 11 | 3.9 | 6 | 9.2 | 7 | 16.7 |
| Palpable splenomegaly | 80 | 20.3 | 39 | 13.6 | 25 | 39.1 | 16 | 37.2 |
| Fatigue | 73 | 19.8 | 44 | 16.5 | 20 | 34.5 | 9 | 20.9 |
| Cardiovascular risk factors | 56 | 12.9 | 38 | 12.2 | 12 | 15.4 | 6 | 13.6 |
| Biology | ||||||||
| Leukocytes (×109/L) | 9 | 2.8-28.1 | 8.9 | 3-28.1 | 9.8 | 2.8-25 | 10.3 | 3-20.9 |
| Hemoglobin (g/L) | 140 | 65-246 | 139 | 99-171 | 174.5 | 134-246 | 132 | 65-168 |
| Platelets (×109/L) | 863 | 99-3290 | 915 | 181-3290 | 601 | 160-1170 | 775 | 99-2036 |
| Mutations | ||||||||
| JAK2V617F | 249 | 56 | 154 | 48.5 | 70 | 86.4 | 25 | 55.6 |
| JAK2 ex 12 | 5 | 1.13 | 0 | 0 | 5 | 6.2 | 0 | 0 |
| JAK2 allele burden | 22 | 1.75-86 | 15.5 | 1.75-86 | 29 | 3.7-77 | 31.8 | 11.8-49 |
| CALR | 59 | 13.3 | 46 | 14.5 | 0 | 0 | 13 | 28.9 |
| MPL | 3 | 0.7 | 3 | 0.9 | 0 | 0 | 0 | 0 |
| Triple negativity | 89 | 20 | 86 | 27 | 0 | 0 | 3 | 6.7 |
| Incomplete or unknown | 39 | 8.8 | 29 | 9.1 | 6 | 7.4 | 4 | 0 |
| Parameters . | Cohort . | ET . | PV . | Other MPNs . | ||||
|---|---|---|---|---|---|---|---|---|
| Nb/median . | % or range . | Nb/median . | % or range . | Nb/median . | % or range . | Nb/median . | % or range . | |
| Numbers | 444 | 318 | 71.6 | 81 | 18.2 | 45 | 10.2 | |
| Female | 321 | 72.3 | 248 | 78 | 39 | 48.1 | 34 | 75.6 |
| Age | 20.4 | 2-25 | 20.6 | 2-25 | 19.7 | 2.3-25 | 20.1 | 5.3-24.4 |
| Symptoms | ||||||||
| Plethoric face | 15 | 3.9 | 2 | 0.7 | 13 | 21.3 | 0 | 0 |
| Aquagenic pruritus | 22 | 5.6 | 9 | 3.2 | 13 | 19.7 | 0 | 0 |
| Hyperviscosity | 127 | 34.5 | 91 | 34.2 | 27 | 42.2 | 9 | 23.7 |
| Microvascular symptoms | 43 | 10.8 | 33 | 11.6 | 4 | 5.8 | 6 | 14 |
| Constit symptoms | 24 | 6.2 | 11 | 3.9 | 6 | 9.2 | 7 | 16.7 |
| Palpable splenomegaly | 80 | 20.3 | 39 | 13.6 | 25 | 39.1 | 16 | 37.2 |
| Fatigue | 73 | 19.8 | 44 | 16.5 | 20 | 34.5 | 9 | 20.9 |
| Cardiovascular risk factors | 56 | 12.9 | 38 | 12.2 | 12 | 15.4 | 6 | 13.6 |
| Biology | ||||||||
| Leukocytes (×109/L) | 9 | 2.8-28.1 | 8.9 | 3-28.1 | 9.8 | 2.8-25 | 10.3 | 3-20.9 |
| Hemoglobin (g/L) | 140 | 65-246 | 139 | 99-171 | 174.5 | 134-246 | 132 | 65-168 |
| Platelets (×109/L) | 863 | 99-3290 | 915 | 181-3290 | 601 | 160-1170 | 775 | 99-2036 |
| Mutations | ||||||||
| JAK2V617F | 249 | 56 | 154 | 48.5 | 70 | 86.4 | 25 | 55.6 |
| JAK2 ex 12 | 5 | 1.13 | 0 | 0 | 5 | 6.2 | 0 | 0 |
| JAK2 allele burden | 22 | 1.75-86 | 15.5 | 1.75-86 | 29 | 3.7-77 | 31.8 | 11.8-49 |
| CALR | 59 | 13.3 | 46 | 14.5 | 0 | 0 | 13 | 28.9 |
| MPL | 3 | 0.7 | 3 | 0.9 | 0 | 0 | 0 | 0 |
| Triple negativity | 89 | 20 | 86 | 27 | 0 | 0 | 3 | 6.7 |
| Incomplete or unknown | 39 | 8.8 | 29 | 9.1 | 6 | 7.4 | 4 | 0 |
Constit, constitutional; ex, exon; MPL, myeloproliferative leukemia; Nb, number.